Dr. Qingping Feng obtained his MD from Southeast University Medical School, China, his PhD in pharmacology from the University of Gothenburg, Sweden, and completed his postdoctoral training at Western University, Canada. He is currently a professor of Physiology, Pharmacology, and Medicine, a Richard & Jean Ivey Chair in Molecular Toxicology at the Schulich School of Medicine and Dentistry, Western University, and a senior scientist at the Lawson Health Research Institute. His research is focused on sepsis, heart failure, and congenital heart defects. His work has elucidated molecular mechanisms of pathogenesis of heart failure and congenital heart defects and has provided a novel strategy for using recombinant human annexin A5 to treat sepsis, which is being tested in clinical trials.